Orexo AB
Quick facts
Marketed products
- Higher bioavailability BNX sublingual tablets · Pain management; Opioid use disorder
BNX is a buprenorphine formulation designed to provide higher bioavailability through sublingual administration, enhancing opioid receptor partial agonism for pain and opioid use disorder treatment. - SL fentanyl
Phase 3 pipeline
- BNX sublingual film · Pain Management / Addiction Medicine
BNX is a buprenorphine sublingual film that binds to opioid receptors to provide analgesia and opioid dependence treatment. - BNX sublingual tablets · Pain Management / Addiction Medicine
BNX is a buprenorphine sublingual tablet that binds to opioid receptors to provide analgesia and opioid dependence treatment. - Buprenorphine/naloxone sublingual tablets · Psychiatry / Addiction Medicine
Buprenorphine acts as a partial mu-opioid receptor agonist while naloxone acts as a mu-opioid receptor antagonist, together providing opioid dependence treatment with abuse-deterrent properties.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: